49 results about "Thrombotic disease" patented technology

The invention relates to a monoclonal antibody with anticoagulant activity and application thereof, the antibody or fragment comprises a light chain variable region and a heavy chain variable region, and the amino acid sequence of the light chain variable region of the antibody or fragment is as shown in SEQ ID NO: 1; the amino acid sequence of the variable region of the heavy chain is as shown in SEQ ID NO: 3. The monoclonal antibody disclosed by the invention has the effect of inhibiting the activity of a co-coagulation pathway in a coagulation cascade reaction, and can be applied to prevention and treatment of thrombotic diseases.

Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.

In one aspect, the invention provides compositions and methods for preventing, reducing, and / or treating a disease, disorder or condition associated with fibrin-induced activation of the complement system and the associated activation of the coagulation and / or contact systems comprising administering a therapeutic amount of a MASP-2 inhibitory antibody to a subject in need thereof. In some embodiments, the methods of the invention provide anticoagulation and / or antithrombosis and / or antithrombogenesis without affecting hemostasis. In one embodiment of this aspect of the invention, the compositions and methods are useful for treating a subject is suffering from, or at risk of developing, a disease, disorder or condition associated with complement-related inflammation, excessive coagulation or contact system activation initiated by fibrin or activated platelets.

A series of sofalcone derivatives are provided.SOLUTION: A series of sofalcone derivatives provided by the present invention are, for example, compounds having a structure of formula (I), and have platelet aggregation inhibitory and antithrombotic effects. The sofalcone derivatives of the present invention are TxA2 receptor antagonists, have an inhibitory effect on platelet agglutination, and do not easily affect the hemostatic function. The present invention also provides a method for preparing the sofalcone derivative, and a method for using the sofalcone derivative for preventing or treating thrombotic diseases, or for inhibiting platelet aggregation.SELECTED DRAWING: None

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

The invention belongs to the technical field of medicines, and discloses application of pantethine in preparation of medicines for preventing and / or treating thrombotic diseases or medicines for inhibiting platelet activation or regulating vascular endothelial cell functions. In-vivo and in-vitro experiments prove that pantethine can remarkably relieve thrombus load in a mouse thrombus model, down-regulate expression of vWF (von Willebrand Factor), up-regulate expression of TFPI (Tissue Factor Path Inhibitor) and TH BD (Thromboregulatory Protein), and antagonize platelet adhesion, aggregation and activation induced by a platelet activator. The action mechanism is closely related to inhibition of reactive oxygen species (ROS) generation and NF-kappa B signal channel activation, and improvement of endothelial cell functions. It can be known from the invention that pantethine plays an antithrombotic role from multiple aspects, and is suitable for preparation of antithrombotic drugs for prevention or treatment. The invention provides a new drug choice for prevention and treatment of thrombotic diseases.

The application provides a highland thrombosis disease risk early warning system, comprising: a sensing acquisition module, which is used for acquiring patient characteristic data, the patient characteristic data including physical sign data and individual baseline data; an index analysis module, which is used for preprocessing the patient characteristic data and generating risk indexes; a risk assessment module, which is used for assessing a risk coefficient according to the risk indexes; and a risk early warning module, which is used for obtaining a risk degree corresponding to the risk coefficient according to a pre-constructed risk classification standard, and implementing corresponding risk early warning according to the risk degree. The application solves the problem in the prior art that a portable health monitoring device cannot accurately measure core hemodynamic parameters closely related to thrombosis, and also cannot accurately perform risk early warning on highland thrombosis diseases according to the acquired parameters.

The invention discloses an application of a TBOA analogue in preparation of a kit for testing platelet stress self-regulating force, and the platelet stress self-regulating force is reflected by the aggregation degree of platelets after being intervened by the TBOA analogue. The application focuses on a new mechanism of platelet activation, that is, when platelets are stimulated by activators such as thrombin, normal reactions of activation and aggregation are driven and maintained by adjusting uptake of glutamic acid by EAATs. Due to the clear action mechanism, the application can provide indexes and methods with higher specificity in diagnosis, treatment and prognosis evaluation of thrombotic diseases, and the pertinence is extremely high. According to the application, the influence of the TBOA analogue on the platelet aggregation degree is utilized to test the stress self-regulating force of the platelet, and new clinical application of the TBOA analogue is developed.

The application discloses a polypeptide FXIa inhibitor FXIapepin with high inhibition and high specificity. Since FXIa can be used as a low hemorrhage risk anti-thrombus treatment target, the polypeptide inhibitor can be used for preparing a drug for developing a low hemorrhage risk treatment or prevention of a thrombotic disease, and has a wide application prospect.

The invention provides an isoquinoline derivative with a novel structure, a pharmaceutically acceptable salt thereof, a preparation method of the isoquinoline derivative, a pharmaceutical composition containing the isoquinoline derivative and pharmaceutical application of the isoquinoline derivative, and belongs to the technical field of medicines. In-vitro experiments show that the isoquinoline derivative has significant inhibitory activity on arachidonic acid-induced platelet aggregation, and the antiplatelet activity of part of compounds is superior to that of aspirin. In a rat carotid artery thrombosis model induced by FeCl3, the isoquinoline derivative remarkably prolongs thrombosis time and reduces thrombus weight, and the in-vivo antithrombotic curative effect of the isoquinoline derivative is equivalent to that of aspirin and ticagrelor. A mouse tail bleeding model shows that the side effects of bleeding amount and bleeding time of the isoquinoline derivative are obviously lower than those of aspirin and ticagrelor. Therefore, the series of isoquinoline derivatives have the advantages of efficient antithrombotic effect and low bleeding risk, and have good application prospects in preparation of drugs for preventing and treating thrombotic diseases. In addition, the preparation method provided by the invention has the advantages of easily available raw materials, simple steps and strong operability, and the obtained target product has high quality and good efficiency.

The application specifically discloses a kind of nanovaccine for thrombosis prevention and its preparation method and application, it is related to thrombotic disease, especially related to the nanovaccine for treating thrombotic disease.The nanovaccine provided by the application has good immunogenicity without macromolecular heterologous protein carrier such as KLH;The process simplicity and repeatability are improved by reducing complex chemical coupling and purification steps;The dependence on traditional high-stimulating immune adjuvant is reduced, and the biological safety is improved;The stability of antigen in gastrointestinal environment is significantly improved;Active targeting delivery of M cells and dendritic cells is realized;Dendritic cell maturation and antigen presentation are promoted, and mucosal immunity and systemic immunity level are improved;The advantages such as effectively inhibiting thrombosis are realized, and a new type of oral antithrombotic vaccine system with high compliance suitable for long-term thrombosis prevention is constructed.

The present invention relates to a monoclonal antibody having an anticoagulant activity and the use thereof. The antibody or a fragment comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the antibody or fragment has an amino acid sequence as shown in SEQ ID NO: 1, and the heavy chain variable region has an amino acid sequence as shown in SEQ ID NO: 3. The monoclonal antibody of the present invention has the effect of inhibiting the activity of a common coagulation pathway in the coagulation cascade reaction, and can be used in the prevention and treatment of thrombotic diseases.

This disclosure relates to 5-amino-2,3-dihydro-1,4-phthalazinedione and its pharmaceutically acceptable salts for the prevention or treatment of thrombotic diseases. The invention particularly relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for this purpose. Pharmaceutical compositions, advantageous formulation techniques, and therapeutic methods are disclosed.

The invention relates to the use of antibodies and antibody that target semaphorin 3A (Sema3A), and fragments thereof, and their use for treating thrombotic diseases of the retina comprising.

This invention provides a gene encoding a coral-derived anticoagulant polypeptide and its applications, belonging to the field of bioactive peptide technology. The invention provides an anticoagulant polypeptide GcKuz1, which includes the mature peptide segment shown in SEQ ID No. 1. The polypeptide GcKuz1 of this invention exerts antithrombotic and anticoagulant effects by binding to KLKB1 in the thrombin system. This polypeptide does not cause hemolysis or cytotoxicity, and has no bleeding risk, exhibiting good biocompatibility. The anticoagulant polypeptide of this invention has therapeutic effects on thrombotic diseases, such as arterial thrombotic diseases, venous thrombotic diseases, and capillary thrombotic diseases.

The invention relates to the field of natural product chemistry, sugar chemistry and biological medicine, and particularly provides glycosaminoglycan and / or a series of derivatives thereof as well as a preparation method and application of the glycosaminoglycan and / or the series of derivatives thereof, the glycosaminoglycan is extracted from starfish glabrata, and the preparation method comprises the following steps: extracting by adopting a papain combined alkaline hydrolysis method; the invention discloses an ALHX-2M series derivative and application of the ALHX-2M series derivative in prevention or treatment of thrombotic diseases, and the ALHX-2M series derivative is obtained by performing separation and purification through ion exchange column chromatography and molecular exclusion column chromatography to obtain ALHX-2M, and further performing deacetylation, deamination and depolymerization treatment and gel column chromatography separation and purification on the ALHX-2M series derivative and the application of the ALHX-2M series derivative in prevention or treatment of thrombotic diseases. The glycosaminoglycan and the derivative thereof take an endogenous blood coagulation factor X enzyme complex (FXase) as an action target, the anticoagulation activity and the antithrombotic activity of the glycosaminoglycan and the derivative thereof are superior to those of low-molecular-weight heparin, the bleeding risk under the equivalent antithrombotic dosage is remarkably reduced, and the glycosaminoglycan and the derivative thereof can be used for medicines or functional foods for preventing and treating thrombotic cardiovascular and cerebrovascular diseases.

The application discloses four kinds of tetra-cyclic compounds with selective adenosine diphosphate inhibition, which have the following formula structure, wherein the amino acids represented by AA are L-Ser residues, L-Glu residues, L-Lys residues and L-Tyr residues respectively, the application discloses a preparation method of the tetra-cyclic compounds and application of the tetra-cyclic compounds in treating arterial thrombosis diseases. Experiments prove that the adenosine diphosphate selective inhibitor has good anti-arterial thrombosis effect. Thus, the application provides an effective technical means for resisting arterial thrombosis.

The invention discloses an anti-recombinant sCD40L murine monoclonal antibody as well as a preparation method and application thereof, and belongs to the field of biological medicines. A recombinant sCD40L is used for immunizing a BALB / c mouse, four cell strains HYD-5048-01-04 capable of stably secreting monoclonal antibodies are obtained through a hybridoma technology, the subtypes of the monoclonal antibodies are IgG1 / kappa and IgG2b / kappa, the Kd value reaches nM level, and heavy and light chain variable region sequences (SEQ ID NO.1-16) are brand new sequences. Through ELISA (enzyme-linked immuno sorbent assay), Western blot and immunohistochemical verification, all the monoclonal antibodies can be specifically combined with the sCD40L. Wherein the F (ab ') 2 fragment (DT1) of 5048-02 can relieve the symptoms of thrombus and organ fibrosis; 5048-03 is used for targeting thrombotic diseases; 5048-02 / 04 has the potential of preventing and treating neurodegenerative diseases, autoimmune diseases and organ transplantation rejection. The monoclonal antibody provided by the invention has high specificity and strong affinity, and a brand new tool is provided for research and development of related drugs.

The invention discloses a sea snake tail glycosaminoglycan as well as a derivative, a pharmaceutically acceptable salt, a preparation method and an application of the sea snake tail glycosaminoglycan. The sea snake tail glycosaminoglycan has a structure as shown in a formula (I), is prepared by extracting, separating and purifying the sea snake tail, and is further subjected to deacetylation, carboxyl reduction, peroxidation depolymerization, deacylation and deamination depolymerization and gel column chromatography to obtain various derivatives of the sea snake tail glycosaminoglycan. The glycosaminoglycan compound and the derivative thereof show remarkable anticoagulation and antithrombotic activity, are low in bleeding risk, mainly act on an endogenous blood coagulation factor X enzyme complex (FXase) and a heparin cofactor II (HCII), and can provide a new thought for preparing medicines or functional foods for treating and / or preventing thrombotic diseases.

The invention belongs to the technical field of traditional Chinese medicine pharmacy, and particularly relates to poecilobdella manillensis freeze-dried powder as well as a preparation method and application thereof. The preparation method of the poecilobdella manillensis freeze-dried powder comprises the following steps: (1) taking living poecilobdella manillensis or freezing and melting the living poecilobdella manillensis, and homogenizing to obtain a poecilobdella manillensis sample solution; (2) carrying out water extraction on the poecilobdella manillensis sample liquid; (3) performing fat extraction on the poecilobdella manillensis precipitate subjected to water extraction; and (4) combining the two extracts to prepare freeze-dried powder. The hirudin content of the poecilobdella manillensis freeze-dried powder prepared by combining a water extraction method with a fat extraction method is remarkably higher than that of a commercially available poecilobdella manillensis product, and the poecilobdella manillensis freeze-dried powder has a remarkable effect on treating thrombotic diseases and other vascular diseases.

1. The name of the design product: full-automatic platelet aggregometer (RealG-PF3 Pro). 2. The use of the design product: a medical testing device for monitoring the efficacy of anti-platelet drugs, identifying and diagnosing bleeding diseases, and monitoring thrombotic diseases. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The application discloses four kinds of tetra-cyclic compounds of four amino acids which selectively inhibit arachidonic acid (AA), and discloses a preparation method of the tetra-cyclic compounds and application of the tetra-cyclic compounds in treating arterial thrombosis diseases. Experiments prove that the arachidonic acid selective inhibitor has good anti-arterial thrombosis effect. Thus, the application provides an effective technical means for resisting arterial thrombosis.

The invention relates to application of alpha-pyrone compounds in preparation of antithrombotic drugs, and belongs to the technical field of biological medicines. The alpha-pyrone compound separated from deep-sea fungus fermentation liquor is applied to the field of prevention and treatment of thrombotic diseases for the first time. After detection, it is found that the compounds 6-((2S, 3S)-2, 3-dihydroxy-2-butyl)-3-methyl-2H-pyran-2-one and 6-ethyl-4-methoxy-3-methyl-2H-pyran-2-one can significantly increase the red blood volume of zebra fish and relieve tail thrombus, and have the ability to resist thrombus, and the compounds 6-((2S, 3S)-2, 3-dihydroxy-2-butyl)-3-methyl-2H-pyran-2-one and 6-ethyl-4-methoxy-3-methyl-2H-pyran-2-one have the ability to resist thrombus; further detection shows that the 6-ethyl-4-methoxy-3-methyl-2H-pyran-2-one can improve the blood flow velocity of a thrombus area and inhibit platelet aggregation, and is low in action concentration, so that the 6-ethyl-4-methoxy-3-methyl-2H-pyran-2-one is small in toxic and side effects, has the potential of developing novel antithrombotic drugs, health-care foods and functional foods, and is wide in market application prospect.

This invention relates to a compound for treating thrombotic diseases. Specifically, this invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, or its enantiomer, diastereomer, transtransferase, racemic mixture, polymorph thereof, solvate thereof, or isotopically labeled derivative thereof. The compound of this invention specifically binds to the SH3 domain protein of Src kinase, interfering with the binding of integrin αIIbβ3 to Src kinase, thereby selectively inhibiting outward-to-inward signal transduction without affecting inward-to-outward signal transduction. This allows the compound of this invention to exert antithrombotic effects without affecting normal physiological hemostasis, avoiding bleeding side effects, and thus becoming a new generation of effective drugs for the prevention and treatment of thrombosis-related cardiovascular and cerebrovascular diseases.

The invention provides 3, 5-substituted imidazo-thiadiazole heterocyclic derivatives as well as a preparation method and application thereof, in particular, a series of 3, 5-substituted imidazo-thiadiazole heterocyclic derivatives are obtained through screening, and the 3, 5-substituted imidazo-thiadiazole heterocyclic derivatives can inhibit eIF4E phosphorylation, reduce generation of p-eIF4E, reduce weight gain, relieve fat accumulation, relieve inflammation and other changes, improve the activity of the 3, 5-substituted imidazo-thiadiazole heterocyclic derivatives and improve the activity of the 3, 5-substituted imidazo-thiadiazole heterocyclic derivatives. The invention also relates to the application of the compound in drugs for preventing and / or treating metabolic diseases, thrombotic diseases, sepsis acute kidney injury, MASLD (Metabolic Fatty Liver Disease), MASH (Metabolic Steatohepatitis) and the like related to eIF4E phosphorylation level imbalance. The metabolic diseases related to eIF4E phosphorylation level imbalance are selected from type 1 diabetes mellitus, type 2 diabetes mellitus, hyperlipidemia, obesity, fatty liver diseases, complications thereof and diseases related to the complications.

The invention discloses an ozagrel-RGDF tetramer with the following structural formula, namely [ozagrel-RGDF] 4, and discloses a preparation method of the ozagrel-RGDF tetramer and application of the ozagrel-RGDF tetramer to treatment of arterial thrombotic diseases. Experiments prove that the [ozagrel-RGDF] 4 disclosed by the invention not only has a good anti-arterial thrombosis effect, but also has no bleeding side effect. Therefore, the invention provides a safe and effective technical means for arterial thrombosis resistance.

A series of sofalcone derivatives having the effect of inhibiting platelet aggregation and antithrombotic effect are disclosed. These sofalcone derivatives are antagonists of TxA2 receptor and have the effect of inhibiting platelet activation and aggregation without causing bleeding. In addition, a preparing method of the sofalcone derivatives and a method for preventing or treating thrombotic diseases or inhibiting platelet aggregation by administrating the sofalcone derivatives are also disclosed.

This invention discloses a sonodynamic synergistic thrombolysis system and its application. The system includes a tissue plasminogen activator variant, a sonosensitive agent, and an ultrasound source. The tissue plasminogen activator variant is an intravenously administered formulation, the sonosensitive agent is an intravenously infused formulation, and the ultrasound source is used to emit ultrasound during sonosensitive agent administration to activate the agent. This invention significantly improves thrombolysis efficiency and reduces thrombolytic agent dosage and bleeding risk through the dual synergistic effect of TNK-tPA enzymatic hydrolysis and sonodynamic chemical oxidation. The system can significantly improve vascular recanalization rate and blood flow velocity recovery rate, and has high biocompatibility. This invention is applicable to thrombolytic treatment of various thrombotic diseases and has the advantages of simple operation, strong targeting, and wide application range.

The invention discloses a thrombus rotary cutting catheter system suitable for multiple lesions, and belongs to the technical field of interventional medical instruments. The system includes a catheter assembly and a powered handle assembly. A composite tool bit, an integrated spiral star-shaped grinding head, a rotary cutting tool bit and a flexible scraper tool bit are arranged at the head end of the catheter assembly and can be selectively used according to thrombus properties; a spiral steel cable with a spiral blade is arranged in the catheter and used for power transmission and thrombus delivery. A driving device, a thrombus outflow pipeline and a guide wire assembly are arranged in the power handle assembly, and the scraper is controlled to be opened and closed through the flexible scraper trigger button. Through the design of the integrated composite tool bit structure, the built-in guide wire and the waste liquid channel, efficient removal of multiple types of thrombus is achieved, catheter replacement in an operation is avoided, and operation continuity and safety are improved. The system is a disposable consumable, is compact in structure, is simple and convenient to operate, and is suitable for interventional therapy of peripheral blood vessel and other thrombotic diseases.

The invention belongs to the technical field of immunodetection analysis, and discloses a kit for quantitative detection of a thrombin-antithrombin III compound and a preparation method of the kit. The kit comprises a magnetic bead working solution, an acridinium ester marker working solution, a biotin marker working solution, a TAT calibrator and a TAT quality control product, and quantitative detection of TAT is realized by combining a double-antibody sandwich method with a chemiluminescence technology. The method overcomes the defects that an existing fluorescence immunoassay method is low in repeatability, and an immunoturbidimetry method is high in requirement for specimens and limited in low-concentration detection capacity, and has the advantages of being high in specificity, sensitivity and accuracy and easy, convenient and rapid to operate. The method can be used for clinical auxiliary diagnosis of thrombogenic diseases such as disseminated intravascular coagulation (DIC) and venous thromboembolism (VTE), and provides a basis for blood coagulation state evaluation and clinical decision making.